Advanced Cancer
Conditions
Keywords
Advanced Cancer, JNJ-61610588
Brief summary
The purpose of this study is to evaluate the safety and tolerability of JNJ-61610588 in participants with advanced cancer in order to determine a recommended Phase 2 dose (RP2D) for further evaluation in specific tumor types.
Detailed description
The purpose of this study is to see if JNJ-61610588 is safe and useful for treating participants with advanced cancer. This study consists of up to 4 parts. Part 1 will determine what dose of JNJ-61610588 can be given safely to advanced cancer participants. Part 2 will look at how participants with metastatic non-small cell lung cancer respond to a safe dose of JNJ-61610588. Parts 3 and 4 will test whether the dose of JNJ-61610588 identified in Part 1 is a safe and effective therapy for participants with specific types of advanced cancers (lung, pancreas, cervical, colorectal, head and neck). Participants will receive study drug in an outpatient setting. Participants safety will be monitored throughout the study.
Interventions
DRUGJNJ-61610588
Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The participant has a solid tumor. Parts 2 and 3 are limited to participants with non-small cell lung cancer. Part 4 is limited to participants with small cell lung, head and neck, pancreatic, colorectal, and cervical cancers * Tumor progression following at least one prior standard therapy * The participant has a radiographically measurable tumor. Evaluable disease is acceptable for Part 1 only * The participant is willing to consent to provide a tumor tissue sample (fresh biopsy) before (Parts 2 and 3) and after (Part 2 only) receiving the study drug * The participant is able to carry out daily life activities without difficulty * The participant does not have significant side effects from previous anti-cancer treatment * The participant has adequate organ and blood cell counts * Sexually active participants must use medically acceptable methods of contraception during the course of this study
Exclusion criteria
* The participant has a history of major surgery or treatment other cancer therapy within 2-6 weeks before starting the study * The participant has an untreated brain tumor * Current severe, uncontrolled systemic disease including an ongoing, active infection requiring treatment with antibiotics * The participant has high blood pressure or diabetes that is not well-controlled with medication * History of clinically significant heart problems * History of severe side effects toimmunotherapy * The participant is pregnant, breastfeeding, or planning to become pregnant or father a child * Positive for Hepatitis B, Hepatitis C, or HIV * The participant has received anticoagulant therapy with the exception of aspirin within 1 week of starting the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Pharmacodynamic Tissue Biomarkers- Markers Associated With Immune Infiltrate Including CD3, CD4, CD8, Forkhead box P3, CD68, and PD-L1. | Approximately 2.5 years | Pre- and posttreatment tissue samples will be stained by immunohistochemistry for markers associated with immune infiltrate including CD3, CD4, CD8, forkhead box P3, CD68, and PD-L1. |
| Frequency of Dose Limiting Toxicity (DLT) | Approximately 2.5 years | The Dose Limiting Toxicity (DLT) is based on adverse events and includes unacceptable hematologic toxicity, unacceptable non-hematologic toxicity of Grade 3 or higher, and treatment delay greater than 2 weeks. |
| Number of Participants with Adverse Events (AEs) and Serious AEs | Approximately 2.5 years | An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. |
| Change From Baseline in Pharmacodynamic Blood Biomarkers- Total Blood Cell Counts | Approximately 2.5 years | Standard hematology laboratory tests will be used to evaluate total blood cell counts in blood samples collected pre- and posttreatment. |
| Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of Monocyte Activation | Approximately 2.5 years | Flow cytometry will be used to evaluate markers of monocyte activation in blood samples collected pre- and posttreatment. |
| Change From Baseline in Pharmacodynamic Blood Biomarkers- Markers of T Cell Activation | Approximately 2.5 years | Flow cytometry will be used to evaluate markers of T cell activation in blood samples collected pre- and posttreatment. |
| Change From Baseline in Pharmacodynamic Tissue Biomarkers- Protein Expression of VISTA (V-domain Ig suppressor of T cell activation) | Approximately 2.5 years | Pre- and posttreatment tissue samples will be stained by immunohistochemistry for protein expression of VISTA. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Serum Concentration (Cmax) of JNJ-61610588 | Approximately 2.5 years | The Cmax is the maximum observed serum concentration of JNJ-61610588. |
| Elimination Half-Life (t1/2) | Approximately 2.5 years | The elimination half-life (t1/2) is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z). |
| Area Under the Serum Concentration-Time Curve From t1 to t2 Time (AUC[t1-t2]) of JNJ-61610588 | Approximately 2.5 years | The AUC(t1-t2) is the area under the serum JNJ-61610588 concentration-time curve from time t1 to t2. |
| Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) | Approximately 2.5 years | The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(last) and C(last)/lambda(z); wherein AUC(last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant. |
| Number of Participants With Anti-JNJ-61610588 Antibodies | Approximately 2.5 years | Plasma levels of antibodies to JNJ-61610588 for evaluation of potential immunogenicity. |
| Assessment of Anti-Tumor Activity, as Assessed by the Overall Response Rate (ORR) | Approximately 2.5 years | Anti-tumour activity as assessed by the ORR based on Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1. |
| Assessment of Anti-Tumor Activity, as Assessed by Duration of Response | Approximately 2.5 years | Anti-tumour activity as assessed by the duration of response. |
Countries
United States
Outcome results
None listed